Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

J Hepatol 2022 Jun 28. Epub 2022 Jun 28.

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.

Background & Aims: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) was shown to predict outcomes of primary biliary cholangitis (PBC) in small-size studies. We aimed to validate the prognostic value of LSM in a large cohort study.

Methods: We performed an international, multicentre, retrospective follow-up study of 3985 patients with PBC seen at 23 centres in 12 countries. Eligibility criteria included at least one reliable LSM by VCTE and a follow-up ≥ 1 year. Independent derivation (n=2740) and validation (n=568) cohorts were built. The primary endpoint was time to poor clinical outcomes defined as liver-related complications, liver transplantation, or death. Hazard ratios (HRs) with confidence intervals (CIs) were determined using a time-dependent multivariable Cox regression analysis.

Results: LSM was independently associated with poor clinical outcomes in the derivation (5324 LSMs, mean follow-up 5.0 ± 3.1 yrs.) and validation (1470 LSMs, mean follow-up 5.0 ± 2.8 yrs.) cohorts: adjusted HRs (95%CI) per additional kPa were 1.040 (1.026-1.054) and 1.042 (1.029-1.056), respectively (p<0.0001 for both). Adjusted C-statistics (95%CI) at baseline were 0.83 (0.79-0.87) and 0.92 (0.89-0.95), respectively. Between 5 and 30 kPa, the log-HR increased as a monotonic function of LSM. The predictive value of LSM was stable in time. LSM improved the prognostic ability of biochemical response criteria, fibrosis scores, and prognostic scores. The 8-kPa and 15-kPa cut-offs optimally separated low, medium, and high-risk groups. Forty percent of patients were at medium to high risk according to LSM.

Conclusions: LSM by VCTE is a major, independent, validated predictor of PBC outcome. Its value as a surrogate endpoint for clinical benefit in PBC should be considered.

Lay Summary: Serum levels of bilirubin and alkaline phosphatase are the only surrogate markers approved by regulatory authorities to assess patients with PBC in therapy trials. Liver histology has been shown to improve prediction of survival beyond these markers but liver biopsy is a potentially harmful, invasive procedure and a serious obstacle to clinical trial recruitment. In the present large, international retrospective cohort study, liver stiffness assessed by vibration-controlled transient elastography was validated as one of the strongest predictive factors of poor clinical outcome in PBC and was shown to improve the prognostic ability of established biochemical markers of treatment response. Studies to evaluate the prognostic impact of LSM changes over time are needed to determine whether LSM can be used as a new surrogate end point for PBC.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jhep.2022.06.017	DOI Listing

June 2022

Publication Analysis

Keyword Occurance

Similar Publications

Primary biliary cholangitis presenting with Fanconi syndrome: an important phenotype.

Authors:

Chaoxui Er Jessica Dyson David Jones John Sayer

BMJ Case Rep 2022 Aug 16;15(8). Epub 2022 Aug 16.

Renal Medicine, Freeman Hospital, Newcastle-upon-Tyne, UK.

A woman in her 50s was referred to nephrology clinic due to progressive chronic kidney disease. She exhibited features of proximal renal tubulopathy, namely Fanconi syndrome, including normoglycaemic glycosuria, normal anion gap metabolic acidosis, and intermittent hypouricaemia and hypophosphataemia. Kidney biopsy showed tubulointerstitial inflammation and focal chronic damage. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis.

Authors:

Usha Gungabissoon Daniel C Gibbons Gema Requena Andrea Ribeiro de Souza Helen Smith

BMJ Open Gastroenterol 2022 Aug;9(1)

Value Evidence and Outcomes (Specialty), GSK, Brentford, UK.

Objective: In order to identify areas of unmet need in patients with primary biliary cholangitis (PBC), this study sought to use real-world observational healthcare data to characterise the burden in patients with PBC and in PBC patients with a recorded diagnosis of pruritus.

Design: This retrospective, cross-sectional database study compared prevalence of prespecified comorbidities and medications in the PBC population and PBC-pruritus subpopulation with non-cases using an indirect standardisation approach. The PBC population was identified from the US IBM MarketScan Commercial Claims and Medicare Supplemental Database during 2016 using International Classification of Diseases 10th Revision, Clinical Modification codes (≥2 claims for PBC); the PBC-pruritus subpopulation additionally had ≥1 claim for pruritus during this period. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Broad vs Narrow Spectrum Antibiotics in Common Bile Duct Stones: A Post Hoc Analysis of an Eastern Association for the Surgery of Trauma Multicenter Study.

Authors:

Brett M Tracy Carrie L Valdez Cameron W Paterson Beth R Hochman Eugenia Kwon Carrie A Sims Rishi Rattan D Dante Yeh Rondi B Gelbard

J Am Coll Surg 2022 Sep 10;235(3):411-419. Epub 2022 Aug 10.

Department of Surgery, University of Alabama at Birmingham, Birmingham, AL (Gelbard).

Background: Antimicrobial guidance for common bile duct stones during the perioperative period is limited. We sought to examine the effect of broad-spectrum (BS) vs narrow-spectrum (NS) antibiotics on surgical site infections (SSIs) in patients with common bile duct stones undergoing same-admission cholecystectomy.

Study Design: We performed a post hoc analysis of a prospective, observational, multicenter study of patients undergoing same-admission cholecystectomy for choledocholithiasis and/or acute biliary pancreatitis between 2016 and 2019. Read More

View Article and Full-Text PDF

September 2022

Similar Publications

Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis.

Authors:

Xiaoling Deng Jiahuan Li Shuhui Hou Bai Ci Beibei Liu Keshu Xu

Ann Hepatol 2022 Aug 12:100746. Epub 2022 Aug 12.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address:

Introduction And Objectives: We performed a systematic review and meta-analysis to evaluate the prevalence of concomitant Sjögren's syndrome (SS) with primary biliary cholangitis (PBC) in adults and quantify the impact of SS on PBC.

Methods: PubMed, Web of Science and Cochrane library were searched using subject terms and predefined inclusion and exclusion criteria.

Results: Seventeen articles were included. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Far From the Biliary Tree: A Case of Overlapping Autoimmune Liver Disease in a Patient Presenting With Sicca Symptoms.

Authors:

Keifer Walsh James Park

Cureus 2022 Jul 11;14(7):e26760. Epub 2022 Jul 11.

Family Medicine, Naval Hospital Camp Pendleton, Oceanside, USA.

Primary biliary cholangitis (PBC) is a chronic autoimmune condition with many extrahepatic manifestations that are commonly encountered as a patient's primary presenting complaints. Rarely, PBC co-exists as an "overlapping syndrome" with other liver-related autoimmune conditions such as autoimmune hepatitis (AIH). Presented is a rare case of PBC with features of AIH diagnosed in a patient who initially presented with hemoptysis and worsened sicca symptoms due to advanced Sjögren's syndrome. Read More

View Article and Full-Text PDF

July 2022

Similar Publications

}

Search Our Scientific Publications & Authors